Traditionally, high-flow oxygen therapy (HFOT) was defined as the delivery of a flow of oxygen higher than 6 L/min. Recently, however, a method has been described in which flows of up to 50 L/ min are delivered through a nasal cannula with a heated humidifier that optimizes oxygen administration. HFOT improves oxygenation by various mechanisms, for instance by decreasing oxygen dilution, reducing respiratory dead space, and generating a continuous positive airway pressure effect. It may also have a beneficial effect on hemodynamics, exercise capacity, and comfort, especially when a nasal cannula is used. HFOT is now a viable treatment option because of the use of heated humidifiers, which allow delivery of conditioned inspiratory gases at 371C and 100% humidity. Properly conditioned gas provides higher comfort and minimizes deterioration of nasopharyngeal structures. Various HFOT systems are currently available. It is important to use the most comfortable device for the patient in question, with the best gas conditioning.
O xygen is one of the most widely used therapeutic agents.
It is a drug in the true sense of the word, with specific biochemical and physiological actions, a distinct range of effective doses, and well-defined adverse effects at high doses. 1 In the critical care setting, technological progress in the area of gas conditioning has been slow in comparison with the innovations introduced in modern mechanical ventilators. Recently, devices using a variety of methods to condition inspiratory gases from an external source have been introduced for use in patients in clinical or home settings. These devices have made it possible to achieve flow rates of up to 50 L/min, delivered through nasal cannula. This system has been used for some years in pediatrics and only recently has begun to be used in adults. The first studies were conducted in children, and in recent years the procedure has also been investigated in adults.
High-flow oxygen therapy (HFOT) improves oxygenation by various mechanisms, for instance by decreasing oxygen dilution, 2 reducing respiratory dead space, 3 and generating a continuous positive airway pressure (CPAP) effect. [4] [5] [6] It may also have beneficial effects on hemodynamics, exercise capacity, and comfort, especially when a nasal cannula is used. 7 There are several commercial companies that supply different types of HFOT equipment. The most important consideration is the ability to deliver high-flow gas conditioning at the level of temperature and humidity, water vapor, that allows tolerance of this treatment. In general, all high-flow devices consist of a water reservoir, a filter, a heater, a system of mixing air and oxygen, and nasal cannula. These nasal cannulas should be semiocclusive, and for this there are different sizes according to the size of the nose. The main differences between equipment are the characteristics of the filter and the tubing connecting the heater to the patient, some of which have characteristics that prevent the ponding of water at that level.
This review is an update of the HFOT using nasal cannula as a therapeutic tool in critically ill hypoxemic patients.
MECHANISMS OF ACTION AND CLINICAL EFFECTS OF HFOT
HFOT offers several potential benefits. 8 First, it removes the air contained in the nasopharyngeal cavity, which is part of the anatomic dead space, allowing better ventilation and oxygenation. Second, it provides an adequate flow to support inspiratory flow demand and may thus reduce inspiratory work of breathing and decrease the dilution of the oxygen delivered with room air. Third, it improves respiratory mechanics by eliminating the effects of drying and cooling. Fourth, it reduces or eliminates the metabolic cost of gas conditioning; this concept refers to the fact that nasal air passages expend energy to warm inspiratory air from ambient to 371C and humidify the incoming air to 100% relative humidity. There is some significant energetic and metabolic cost to this process of gas conditioning. This cost is alleviated when gas is delivered at body temperature and saturated by, for example, an HFOT system. Finally, it may be associated with some end-level distending pressure. Although one report has shown no increases in the inspired oxygen fraction (FiO 2 ) when flows higher than 6 L/min were administered, 9 the majority have observed higher FiO 2 with increased oxygen flow delivery 2 (Figs. 1A, B ).
The latter result suggests a reduction in the dilution of the administered oxygen by room air. The aim with HFOT is to meet the patients' peak inspiratory flow rate [peak inspiratory demand (PID)]. At this rate, all the inhaled gas will consist of the fully humidified air containing the prescribed FiO 2 . During normal, quiet breathing, PID is around 30 to 40 L/min. 10 This is the flow range recommended for HFOT. For patients with distress, this is not going to meet their PID, but it will provide the majority of the breath with humidified and oxygenenriched gas. In addition, it has been found that high flows of oxygen-enriched gas delivered nasally are more efficacious than the nonrebreather mask at the same flows. 11 It is believed that the continuous flow of gas through the nasopharynx washes out oxygen depleted air, so that the upper airway in effect becomes a reservoir of oxygen-enriched gas. Oxygen dilution is especially important when large tidal volumes or high peak inspiratory flows are used, as may occur in acute respiratory failure (ARF). Moreover, it may explain, at least in part, the improvement in oxygenation reported in patients with ARF treated with HFOT. 7, 12, 13 Similarly, by minimizing or preventing air entrainment and dilution of the oxygen delivered, it may be possible to achieve a better control of the delivered oxygen concentrations. Besides increased FiO 2 , other factors that may play some role in the oxygenation improvement observed with HFOT in these patients are the reduction in the dead space 3 and the decrease in ventilatory demand caused by the combination of the decreased oxygen consumption because of respiration and metabolic download or, in other words, the oxygen utilized in the work of breathing at higher minute volumes. 4 HFOT administration causes a degree of positive pressure in the airway that could be considered a CPAP effect. [4] [5] [6] Interestingly, it may be useful in certain pathologic situations such as hypoxemic ARF and pulmonary edema. This positive pressure, which may reach 7 cm H 2 O with 50 L/min, correlated directly with the flow administered: the higher the flows delivered, the higher the CPAP effect achieved. Furthermore, higher CPAP levels were found in women and with the mouth closed. At the same given flow of 40 to 60 L/min, 2 to 3 cm H 2 O of median expiratory pharyngeal pressure was recorded with the mouth open, compared with 5 to 7 cm H 2 O with the mouth closed. More recently, in a series of postcardiac surgical patients HFOT was associated with an increase in the end expiratory lung impedance and, therefore, in the end expiratory lung volumes. 14 The effect on the FiO 2 administered of keeping the mouth open is still controversial. Although some studies reported no significant changes, 15 other authors found increased administered FiO 2 with the mouth closed. 16, 17 More recently, Wettstein et al 2 found that the FiO 2 administered may be even higher with the mouth open. Thus, at present there is no consensus on the issue.
Finally, it has been shown that HFOT may be associated with an improvement in exercise performance, a reduction in dyspnea, better breathing patterns with a decrease in respiratory rate, and lower arterial pressure. 4 
ADVANTAGES OF HFOT
High-flow treatment allows delivery of high FiO 2 with an associated mild CPAP effect. [4] [5] [6] High flows can be delivered through a noninvasive nasal cannula made of a very adaptable material applied to the nostrils. Thus, in severely hypoxemic patients, HFOT can be considered as an intermediate step between conventional oxygen therapy and noninvasive ventilation (NIV) (Fig. 2) . The device is more comfortable and less claustrophobic than other conventional NIV interfaces, and is a user-friendly system for both patients and health care workers. For all these reasons, HFOT may have a role in various clinical environments, such as critical care departments, pneumology, internal medicine, surgical wards, postoperative recovery rooms, emergency departments, and also in extrahospital transfers.
High-flow therapy allows administration of conditioned gases, increasing tolerance of patients, and optimizing respiratory function. In fact, heated humidification systems may attenuate the development of bronchial hyperresponse symptoms. 18 The nasal cannula allows verbal communication and even oral administration. In this regard, HFOT is associated with an improvement in overall comfort in ARF patients. Recently, Tiruvoipati et al 19 demonstrated that high-flow therapy was better tolerated when it was delivered through a nasal cannula than through a face mask. For all these reasons, HFOT may well be a useful treatment in the general management of ARF patients.
MAIN CLINICAL INDICATIONS OF HFOT IN ADULTS
HFOT may be indicated in several situations (Table 1) . First, it is indicated in all situations that require delivery of high oxygen concentrations. 13 Second, it is particularly useful when the administration of totally conditioned gas may be beneficial, for example, in patients with respiratory infections, chronic obstructive pulmonary disease (COPD), or bronchial asthma. Correct airway humidification improves the mucociliary function, increasing mucus clearance and decreasing atelectasis formation. Third, the high FiO 2 administration achieved with HFOT allows the practice of diagnostic and therapeutic procedures such as fiberoptic bronchoscopy 20 and transesophageal echocardiography, which otherwise may not be tolerated or may have required prior endotracheal intubation and mechanical ventilation. Fourth, it may be useful during weaning from mechanical ventilation, especially in postsurgical patients, and The aim with HFOT is to meet the patients' peak inspiratory flow rate (PID). At this rate all the inhaled gas will consist of the fully humidified air containing the prescribed FiO 2 . In gray, oxygen; in white, room air. During normal, quiet breathing, PID is around 30 to 40 L/min. This is the flow range recommended for HFOT. With this, delivered FiO 2 is equal to real FiO 2 , whereas with low-flow oxygen, real FiO 2 may be lower than the delivered one. FiO 2 indicates fraction of inspired oxygen; PID, peak inspiratory demand.
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Clinical Pulmonary Medicine Volume 19, Number 3, May 2012 also while placing the nasal cannula before extubation. 12 Fifth, it can be used in patients who report discomfort with conventional masks. 21 Finally, it is a treatment that can be used in patients with a do-not-intubate order.
HFOT is likely to avoid the need for health care resources such as NIV or sophisticated invasive mechanical ventilation. Recent results suggest that it may reduce the need for endotracheal intubation and provide an effective and a more comfortable alternative to NIV in patients with ARF. 12, 13, 22, 23 
WEANING FROM HFOT
It is difficult to give clear indications for HFOT weaning and for the replacement of therapy by a system of conventional low-flow oxygen. However, it seems advisable first to decrease FiO 2 and then the flow delivered. We recommend maintaining the flow rate until correct oxygenation with FiO 2 of < 0.5 is achieved. Then, a slow flow reduction (5 to 10 L/min every few hours) should be initiated. Finally, when correct oxygenation is obtained with 20 L/min or less at a given FiO 2 < 0.5, HFOT can be replaced by a conventional oxygen device. 24 Nevertheless, some patients may need intermittent HFOT application during the HFOT weaning phase.
CONTRAINDICATIONS AND COMPLICATIONS OF HFOT
No important adverse effects related with HFOT systems have been reported. Heated humidifiers allow delivery of conditioned gases and so the deterioration of nasopharyngeal structures at these high flow rates is minimized. In COPD patients, delivery of high oxygen concentration may induce hypercapnia by reducing respiratory rate, altering ventilationperfusion relationships and perhaps by increasing gas viscosity and density. 25 The possible effect of HFOT in COPD patients has not been well defined. Recently, it has been shown that titrated oxygen treatment in the prehospital setting resulted in a 78% reduction in the risk of in-hospital respiratory failure and subsequent mortality compared with high-flow oxygen treatment in COPD patients. 26 However, 8 to 10 L/min of oxygen was administered in the high flow rate arm; consequently, although treatment improved oxygenation, it was also associated with an increase in respiratory acidosis. No data are currently available on treating COPD patients with high flow rates with lower FiO 2 , keeping oxygen saturation between 88% and 92%.
Various high-flow systems are available. One should use the most comfortable device for the patient, with the bestheated humidification system. The systems should prevent or at least minimize water stagnation, which may lead to the appearance of infections, for example the outbreaks of colonization or infection with Ralstonia reported by Schultz. 27 
VALL D'HEBRON UNIVERSITY HOSPITAL EXPERIENCE
Our general intensive care unit with 34 medicosurgical beds uses HFOT in adults for a few years, mainly in patients with ARF of various etiologies, in patients suffering from pneumonia, and in some immunocompromised patients (oncology and hematologic patients and readmissions for lung transplant ARF), with very good results. Patients tolerate the system very well, with excellent comfort, 7 and we also use this system in hypoxemic patients when some invasive diagnostic techniques such as bronchoscopy or transesophageal echocardiography are needed. 20 Moreover, as Schibler et al 28 reported in a pediatric population, we think that this system may avoid some intubations and mechanical ventilation.
We use the Fisher & Paykel system without water stagnation problems. We start with a flow of 30 L, which can usually go up to 40 L/min, with FiO 2 = 1, which we modify according to the pulse oximetry. The weaning is done when FiO 2 is < 0.5 and < 20 L/min flow is used, and then we can replace this system with one of the conventional low-flow oxygen therapies.
SUMMARY
In conclusion, HFOT is now a viable treatment option thanks to heated humidification devices that allow the administration of properly conditioned gases, increasing patients' comfort and minimizing the deterioration of nasopharyngeal structures. The choice of the best-suited high-flow device is also important; it should be the most comfortable for the patient, with best possible gas conditioning, and should be able to prevent water stagnation in the system to reduce the appearance of complications. We believe that HFOT is an attractive and useful treatment option in patients with ARF, improving oxygenation and patient comfort and reducing the respiratory rate. However, further studies are needed to determine its possible impact on patients' general outcomes. 
